Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates
Tumor cell lysates (TCLs) are a good immunogenic source of tumor-associated antigens. Since whole necrotic TCLs can enhance the maturation and antigen-presenting ability of dendritic cells (DCs), multiple strategies for the exogenous delivery of TCLs have been investigated as novel cancer immunother...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/7/1358 |
| _version_ | 1827618709125988352 |
|---|---|
| author | Jihyun Seong Kyobum Kim |
| author_facet | Jihyun Seong Kyobum Kim |
| author_sort | Jihyun Seong |
| collection | DOAJ |
| description | Tumor cell lysates (TCLs) are a good immunogenic source of tumor-associated antigens. Since whole necrotic TCLs can enhance the maturation and antigen-presenting ability of dendritic cells (DCs), multiple strategies for the exogenous delivery of TCLs have been investigated as novel cancer immunotherapeutic solutions. The TCL-mediated induction of DC maturation and the subsequent immunological response could be improved by utilizing various material-based carriers. Enhanced antitumor immunity and cancer vaccination efficacy could be eventually achieved through the in vivo administration of TCLs. Therefore, (1) important engineering methodologies to prepare antigen-containing TCLs, (2) current therapeutic approaches using TCL-mediated DC activation, and (3) the significant sequential mechanism of DC-based signaling and stimulation in adaptive immunity are summarized in this review. More importantly, the recently reported developments in biomaterial-based exogenous TCL delivery platforms and co-delivery strategies with adjuvants for effective cancer vaccination and antitumor effects are emphasized. |
| first_indexed | 2024-03-09T10:13:18Z |
| format | Article |
| id | doaj.art-4cd2e52c67dc48018e8dd193e9809663 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T10:13:18Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-4cd2e52c67dc48018e8dd193e98096632023-12-01T22:34:07ZengMDPI AGPharmaceutics1999-49232022-06-01147135810.3390/pharmaceutics14071358Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell LysatesJihyun Seong0Kyobum Kim1Department of Chemical and Biochemical Engineering, Dongguk University, 30 Pildong-ro 1-gil, Jung-gu, Seoul 22012, KoreaDepartment of Chemical and Biochemical Engineering, Dongguk University, 30 Pildong-ro 1-gil, Jung-gu, Seoul 22012, KoreaTumor cell lysates (TCLs) are a good immunogenic source of tumor-associated antigens. Since whole necrotic TCLs can enhance the maturation and antigen-presenting ability of dendritic cells (DCs), multiple strategies for the exogenous delivery of TCLs have been investigated as novel cancer immunotherapeutic solutions. The TCL-mediated induction of DC maturation and the subsequent immunological response could be improved by utilizing various material-based carriers. Enhanced antitumor immunity and cancer vaccination efficacy could be eventually achieved through the in vivo administration of TCLs. Therefore, (1) important engineering methodologies to prepare antigen-containing TCLs, (2) current therapeutic approaches using TCL-mediated DC activation, and (3) the significant sequential mechanism of DC-based signaling and stimulation in adaptive immunity are summarized in this review. More importantly, the recently reported developments in biomaterial-based exogenous TCL delivery platforms and co-delivery strategies with adjuvants for effective cancer vaccination and antitumor effects are emphasized.https://www.mdpi.com/1999-4923/14/7/1358tumor cell lysateadjuvantdendritic cellexogenous delivery systemcancer immunotherapy |
| spellingShingle | Jihyun Seong Kyobum Kim Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates Pharmaceutics tumor cell lysate adjuvant dendritic cell exogenous delivery system cancer immunotherapy |
| title | Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates |
| title_full | Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates |
| title_fullStr | Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates |
| title_full_unstemmed | Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates |
| title_short | Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates |
| title_sort | activation of cellular players in adaptive immunity via exogenous delivery of tumor cell lysates |
| topic | tumor cell lysate adjuvant dendritic cell exogenous delivery system cancer immunotherapy |
| url | https://www.mdpi.com/1999-4923/14/7/1358 |
| work_keys_str_mv | AT jihyunseong activationofcellularplayersinadaptiveimmunityviaexogenousdeliveryoftumorcelllysates AT kyobumkim activationofcellularplayersinadaptiveimmunityviaexogenousdeliveryoftumorcelllysates |